Back to Search Start Over

Success and risks of pregnancy after breast cancer.

Authors :
Leproux C
Seegers V
Patsouris A
Sauterey B
Source :
Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Aug; Vol. 188 (3), pp. 593-600. Date of Electronic Publication: 2021 Apr 21.
Publication Year :
2021

Abstract

Introduction: Breast cancer is the most common cancer in women worldwide. The number of childbearing-age women diagnosed with early breast cancer (eBC) is increasing, raising questions over their subsequent fertility.<br />Purpose: The main objective of this study was therefore to assess, in a cohort of eBC patients with pregnancy desire, the rate of live births achieved spontaneously or by assisted reproductive technology.<br />Methods: We conducted an observational, descriptive, retrospective study including patients aged 18-40, treated for eBC at the Institut de Cancérologie de l'Ouest (ICO) Pays de Loire between July 2010 and July 2016, with pregnancy desire. The primary outcome was the rate of live births. Secondary outcomes were overall survival, disease-free survival, time to conception, and spontaneous or assisted pregnancy rate.<br />Results: 61 patients were included, with a live birth rate of 19.7% (12/61). We observed no recurrence or death in women with a pregnancy. Pregnancy started with a median time of 36.4 months after the end of treatment (4.1-51.3 months). All pregnancies in this cohort were achieved spontaneously.<br />Conclusion: The results of our cohort are consistent with previous results showing that spontaneous pregnancy remains possible after treatment for eBC without increasing the risk of recurrence or death.<br /> (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1573-7217
Volume :
188
Issue :
3
Database :
MEDLINE
Journal :
Breast cancer research and treatment
Publication Type :
Academic Journal
Accession number :
33884537
Full Text :
https://doi.org/10.1007/s10549-021-06232-5